The relationship between DC-CIK and colorectal cancer prognoses and its influencing factors

CAO Yue; YANG Xijing; ZHOU Fuping; ZHANG Qian; QIAN Qijun

doi:10.3969/j.issn.1006-0111.2016.04.022

Message Board

Respected readers, authors and reviewers, you can add comments to this page on any questions about the contribution, review, editing and publication of this journal. We will give you an answer as soon as possible. Thank you for your support!

Name

E-mail

Phone

Title

Content

Verification Code

Objective To discuss dendritic cell-cytokine-induced killer (DC-CIK) cell therapy effects and clinical outcomes in patients with colorectal cancer in order to have better clinical treatment. Methods A retrospective analysis of the data of 66 patients with colorectal cancer from the Biological Therapy Department of the Eastern Hepatobiliary Surgery Hospital was performed from January 2012 to January 2014, and then was followed up. Taking gender, age, degree of pathological differentiation, TNM staging, surgical methods, and targeted therapy as the research basis, by the Kaplan-Meier single factor and Cox multiple factors analysis we mainly discuss the DC-CIK cell treatment's effect on the prognoses of patients. Results Kaplan-Meier single factor analysis results indicate:to a certain extent, DC-CIK cell therapy can improve the prognoses of patients; Cox multi-factor analysis results indicate whether accepting DC-CIK cell therapy is an independent factor influencing the prognoses of patients. Conclusion DC-CIK cells therapy can improve the prognoses of patients with colorectal cancer.

The relationship between DC-CIK and colorectal cancer prognoses and its influencing factors

1. First Clinical Medical College, Fujian Medical University, Fuzhou 350108, China

2. Laboratory of Gene and Viral Therapy, Department of Biotherapy, Eastern Hepatobiliary Surgery Hospital Affiliated to Second Military Medical University, Shanghai 200438, China

Received Date: 2016-04-08

Rev Recd Date: 2016-05-17

Key words:

colorectal cancer /
prognosis /
dendritic cell-cytokine-induced killers (DC-CIK) /
drug targeting therapy

Abstract: Objective To discuss dendritic cell-cytokine-induced killer (DC-CIK) cell therapy effects and clinical outcomes in patients with colorectal cancer in order to have better clinical treatment. Methods A retrospective analysis of the data of 66 patients with colorectal cancer from the Biological Therapy Department of the Eastern Hepatobiliary Surgery Hospital was performed from January 2012 to January 2014, and then was followed up. Taking gender, age, degree of pathological differentiation, TNM staging, surgical methods, and targeted therapy as the research basis, by the Kaplan-Meier single factor and Cox multiple factors analysis we mainly discuss the DC-CIK cell treatment's effect on the prognoses of patients. Results Kaplan-Meier single factor analysis results indicate:to a certain extent, DC-CIK cell therapy can improve the prognoses of patients; Cox multi-factor analysis results indicate whether accepting DC-CIK cell therapy is an independent factor influencing the prognoses of patients. Conclusion DC-CIK cells therapy can improve the prognoses of patients with colorectal cancer.

HTML

Reference (22)

[1]	陈勇. 口服单药希罗达与FOLFOX方案治疗晚期结直肠癌的疗效比较[J]. 中国药业,2012,21(11):90-91.
[2]	Thara E, Dorff TB, Pinski JK, et al. Vaccine therapy with sipuleucel-T (provenge) for prostate cancer[J]. Maturitas,2011,69(4):296-303.
[3]	Fox BA, Schendel DJ, Butterfield LH, et al. Defining the critical hurdles in cancer immunotherapy[J]. J Transl Med,2011,9:214.
[4]	Bol KF, Tel J, de Vries IJM, et al. Naturally circulating dendritic cells to vaccinate cancer patients[J]. Oncoimmunology,2013,2(3):e23431.
[5]	Tel J, Smits EL, Anguille S, et al. Human plasmacytoid dendritic cells are equipped with antigen-presenting and tumoricidal capacities[J]. Blood,2012,120(19):3936-3944.
[6]	Wang X, Yu W, Li H, et al. Can the dual-functional capability of CIK cells be used to improve antitumor effects?[J]. Cell Immunol,2014,287(1):18-22.
[7]	Frankenberger B, Schendel DJ. Third generation dendritic cell vaccines for tumor immunotherapy[J]. Eur J Cell Biol,2012,91(1):53-58.
[8]	Mesiano G, Todorovic M, Gammaitoni L, et al. Cytokine-induced killer (CIK) cells as feasible and effective adoptive immunotherapy for the treatment of solid tumors[J]. Expert Opin Biol Ther,2012,12(6):673-684.
[9]	Jakel CE, Hauser S, Rogenhofer S, et al. Clinical studies applying cytokine-induced killer cells for the treatment of renal cell carcinoma[J]. Clin Dev Immunol,2012,2012:473245.
[10]	Mesiano G, Todorovic M, Gammaitoni L, et al. Cytokine-induced killer (CIK) cells as feasible and effective adoptive immunotherapy for the treatment of solid tumors[J]. Expert Opin Biol Ther,2012,12(6):673-684.
[11]	Shi S, Wang R, Chen Y, et al. Combining antiangiogenic therapy with adoptive cell immunotherapy exerts better antitumor effects in non-small cell lung cancer models[J]. PLoS One,2013,8(6):e65757.
[12]	Hasumi K, Aoki Y, Wantanabe R, et al. Clinical response of advanced cancer patients to cellular immunotherapy and intensity-modulated radiation therapy[J]. Oncoimmunology,2013,2(10):e26381.
[13]	Hontscha C, Borck Y, Zhou H, et al. Clinical trials on CIK cells:first report of the international registry on CIK cells (IRCC)[J]. J Cancer Res Clin Oncol,2011,137(2):305-310.
[14]	Thanendrarajan S, Nowak M, Abken H, et al. Combining cytokine-induced killer cells with vaccination in cancer immunotherapy:more than one plus one?[J]. Leuk Res,2011,35(9):1136-1142.
[15]	Schlom J. Recent advances in therapeutic cancer vaccines[J]. Cancer Biother Radiopharm,2012,27(1):2-5.
[16]	Marten A, Renoth S, von Lilienfeld-Toal M, et al. Enhanced lytic activity of cytokine-induced killer cells against multiple myeloma cells after co-culture with idiotype-pulsed dendritic cells[J]. Haematologica,2001,86(10):1029-1037.
[17]	Xiang B, Snook AE, Magee MS, et al. Colorectal cancer immunotherapy[J]. Discov Med,2013,15(84):301-308.
[18]	Toomey PG, Vohra NA, Ghansah T, et al. Immunotherapy for gastrointestinal malignancies[J]. Cancer Control,2013,20(1):32-42.
[19]	Cui Y, Yang X, Zhu W, et al. Immune response, clinical outcome and safety of dendritic cell vaccine in combination with cytokine-induced killer cell therapy in cancer patients[J]. Oncol Lett,2013,6(2):537-541.
[20]	Mesiano G, Todorovic M, Gammaitoni L, et al. Cytokine-induced killer (CIK) cells as feasible and effective adoptive immunotherapy for the treatment of solid tumors[J]. Expert Opin Biol Ther,2012,12(6):673-684.
[21]	Duru N, Fan M, Candas D, et al. HER2-associated radioresistance of breast cancer stem cells isolated from HER2-negative breast cancer cells[J]. Clin Cancer Res,2012,18(24):6634-6647.
[22]	Beutler N, Hauka S, Niepel A, et al. A natural tapasin isoform lacking exon 3 modifies peptide loading complex function[J]. Eur J Immunol,2013,43(6):1459-1469.

Message Board

The relationship between DC-CIK and colorectal cancer prognoses and its influencing factors

doi: 10.3969/j.issn.1006-0111.2016.04.022

Abstract

References

Proportional views

通讯作者: 陈斌, bchen63@163.com

Article Metrics

Related

Proportional views